-transparent.png){kind=logo}
Eleven patients with hepatic cirrhosis or cholestasis were treated with rifampicin for 7 to 132 days. Ten patients received hexobarbital (7.32 mg/kg) and five received tolbutamide (20 mg/kg) by i.v. infusion prior to and after rifampicin treatment; plasma concentrations of the two test compounds were determined during and after infusion. The average elimination half-life of hexobarbital had decreased from 624 to 262 min and that of tolbutamide from 292 to 160 min following rifampicin treatment. It was calculated that the metabolic clearance of hexobarbital had increased more than two-fold and that of tolbutamide almost two-fold. The results suggests that rifampicin is able to stimulate hepatic drug metabolism in patients with liver disease. It was apparent in general that the induction did not lead to improvement of hepatocellular function during disease as judged by laboratory findings.
W Zilly, and
D D Breimer, and
E Richter
August 1981,
Digestive diseases and sciences,
W Zilly, and
D D Breimer, and
E Richter
January 1976,
Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
W Zilly, and
D D Breimer, and
E Richter
January 1976,
Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
W Zilly, and
D D Breimer, and
E Richter
January 1981,
Drug metabolism and disposition: the biological fate of chemicals,
W Zilly, and
D D Breimer, and
E Richter
November 1991,
Xenobiotica; the fate of foreign compounds in biological systems,
W Zilly, and
D D Breimer, and
E Richter
July 1970,
Nihon yakurigaku zasshi. Folia pharmacologica Japonica,
W Zilly, and
D D Breimer, and
E Richter
January 1969,
JAMA,
W Zilly, and
D D Breimer, and
E Richter
March 1971,
Annals of allergy,
W Zilly, and
D D Breimer, and
E Richter
January 1985,
European journal of clinical pharmacology,
W Zilly, and
D D Breimer, and
E Richter
March 1978,
Gastroenterology,
